News and Announcements
Ironwood Begins Phase I Trial of Investigation IW-2143 Anxiety Drug in US
- Published December 21, 2012 7:44PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bionomics Limited (ASX: BNO) (ADR: BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has begun in the US.
The trial is designed to assess the safety and pharmacokinetics of IW-2143 in healthy volunteers, using single and multi-dose administration.
—–
To view the full article, please click here.